Company intelligence / Profile preview

Parasol Biotech

Ownership: Private
Development stage: Other

Overview

Parasol Biotech is a private Chinese biotech company developing CAR-T cell therapies targeting the guanylate cyclase 2C receptor for solid tumors. At ASCO 2023, they reported six remissions among ten evaluable colorectal cancer patients treated with their GUCY2C-targeted CAR-T product. Two additional non-evaluable patients died during the study—one from bone marrow failure and one from Covid[4].

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

anti-GUCY2C CAR-T cells

Unknown

Beyond the preview

Go deeper on Parasol Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parasol Biotech.

Explore the full profile